<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2065">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650191</url>
  </required_header>
  <id_info>
    <org_study_id>15456</org_study_id>
    <nct_id>NCT04650191</nct_id>
  </id_info>
  <brief_title>Surfactant Protein Genetic Variants in COVID-19 Infection</brief_title>
  <official_title>Surfactant Protein Genetic Variants in COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surfactant protein plays important role in innate immunity against respiratory viral&#xD;
      infections. However, investigators have shown that the surfactant protein polymorphisms are&#xD;
      associated with severity of various pulmonary diseases such as respiratory syncytial virus&#xD;
      (RSV), tuberculosis, pediatric acute lung injury. COVID-19 virus gains entry through the&#xD;
      respiratory system and responsible for death due to acute respiratory failure. There is a&#xD;
      considerable heterogeneity in presentation of COVID-19 infection from asymptomatic patients&#xD;
      to severe infection requiring intensive care and some may die. Considering reports of&#xD;
      COVID-19 related deaths/severe disease in the same family, it is possible that genetics play&#xD;
      an important role in severity of COVID-19 infection. Investigators propose to study the&#xD;
      association of surfactant proteins in COVID-19 patients. Key Objectives: a) Characterize&#xD;
      genetic markers within the surfactant protein genes in COVID-19 positive patients, b) To&#xD;
      determine if there is a correlation between certain genetic markers and the severity of&#xD;
      COVID-19 infection which may be used as a prognostic marker, c) To correlate genetic markers&#xD;
      with immune studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Correlation of surfactant protein genetic variants with severity of COVID-19 infection</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Mild COVID-19 infection</arm_group_label>
    <description>Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate COVID-19 infection</arm_group_label>
    <description>Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe COVID-19 infection</arm_group_label>
    <description>Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Identification of genetic variants</intervention_name>
    <description>DNA will be extracted from whole blood from study subjects</description>
    <arm_group_label>Mild COVID-19 infection</arm_group_label>
    <arm_group_label>Moderate COVID-19 infection</arm_group_label>
    <arm_group_label>Severe COVID-19 infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA will be stored for the future studies.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with positive COVID-19 infection will be enrolled regardless of age and sex after&#xD;
        obtaining informed consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The major inclusion criteria is a confirmed diagnosis of COVID-19 infection performed on&#xD;
        nasopharyngeal secretions by enzyme immunoassay or culture in patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients unable to sign informed consent will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chintan K Gandhi, MD, MBBS</last_name>
    <phone>7175318413</phone>
    <email>cgandhi@pennstatehealth.psu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Milton S. Hershey Medical center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chintan K Gandhi, MD, MBBS</last_name>
      <phone>717-531-8413</phone>
      <email>cgandhi@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Chintan Gandhi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified data will be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

